# Core B - Biospecimen/Pathology Core

> **NIH NIH P50** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $250,990

## Abstract

PROJECT SUMMARY
The goal of the NYU Melanoma SPORE Core B (Biospecimen Procurement & Utilization Core) is to stimulate
patient-centered melanoma translational research by providing all NYU Melanoma SPORE investigators—
including research project co-leaders, Career Enhancement Program (CEP) awardees, and Developmental
Research Program (DRP) awardees—with both: 1) access to high-quality melanoma biospecimens linked to
prospectively collected clinical and pathological data, and 2) innovative services that promote the aims of those
projects. Core B will maintain and expand the clinicopathological data and corresponding biospecimen (tissue,
blood, and stool) resources of the NYU Melanoma Clinicopathological-Biospecimen Database and Repository
for the SPORE’s study of resected and unresectable metastatic melanoma patients. To execute the central
scientific strategy of the NYU Melanoma SPORE, Core B will coordinate with industry partners to ensure the
acquisition, processing, and distribution of nearly 10,000 human biospecimens from melanoma patients enrolled
in multi-site phase III clinical trials. Core B will process biospecimens, including performing nucleic acid extraction
and T-cell isolation, and provide specialized, innovative pathology services to support the aims of full SPORE
research projects, CEP projects, and DRP projects. Through a governance committee, Core B will also provide
oversight of SPORE biospecimen use. Building on the NYU Melanoma Clinicopathological-Biospecimen
Database and Repository’s infrastructure, biospecimen resources, and extensive support of NYU Melanoma
Program studies internally and with other institutions, Core B will stimulate collaborations within the NYU
Melanoma SPORE community as well as with outside collaborators, including other currently active Melanoma
and Skin Cancer SPOREs.
Given the considerable translational research infrastructure and resources at NYU, Core B personnel will also
work closely with the Administrative Core to ensure the most efficient use of institutional resources without
replication of efforts.
Overall, Core B will provide high quality, annotated melanoma patient biospecimens to all SPORE studies to
support the NYU Melanoma SPORE’s mission to develop clinically impactful prognostic and predictive
biomarkers for the personalized management of resectable melanoma patients.

## Key facts

- **NIH application ID:** 10200698
- **Project number:** 5P50CA225450-03
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Iman Osman
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $250,990
- **Award type:** 5
- **Project period:** 2019-07-19 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10200698

## Citation

> US National Institutes of Health, RePORTER application 10200698, Core B - Biospecimen/Pathology Core (5P50CA225450-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10200698. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*